Holen Sie sich die Stockscreener-App
31.74
0.57%
0.18
Handel nachbörslich:
31.88
0.14
+0.44%
Schlusskurs vom Vortag:
$31.56
Offen:
$31.66
24-Stunden-Volumen:
109.98K
Relative Volume:
0.79
Marktkapitalisierung:
$502.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-61.23M
KGV:
-2.3477
EPS:
-13.5194
Netto-Cashflow:
$22.49M
1W Leistung:
-5.94%
1M Leistung:
-11.02%
6M Leistung:
+69.55%
1J Leistung:
+87.37%
1-Tages-Spanne:
$31.26
$33.71
1-Wochen-Bereich:
$29.31
$33.71
52-Wochen-Spanne:
$7.75
$39.70
Assembly Biosciences Inc Stock (ASMB) Company Profile
Firmenname
Assembly Biosciences Inc
Sektor
Branche
Telefon
(833) 409-4583
Adresse
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Vergleichen Sie ASMB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
31.74 | 499.19M | 0 | -61.23M | 22.49M | -13.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-24 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-08-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-03-25 | Eingeleitet | Guggenheim | Buy |
| 2024-09-20 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-13 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-09-02 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2020-10-19 | Eingeleitet | Truist | Buy |
| 2019-10-16 | Eingeleitet | Mizuho | Buy |
| 2018-11-19 | Eingeleitet | Leerink Partners | Outperform |
| 2018-10-08 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-08-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-04-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Neutral |
| 2017-11-08 | Eingeleitet | Jefferies | Buy |
| 2017-05-30 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Assembly Biosciences Inc Aktie (ASMB) Neueste Nachrichten
Assembly Biosciences stock jumps after Wall Street says Gilead opt-in ‘significantly de-risks’ genital herpes programs - MSN
Assembly Biosciences (ASMB) price target increased by 24.84% to 48.70 - MSN
Assembly Biosciences (NASDAQ:ASMB) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
How strong is Assembly Biosciences Inc. stock revenue growthWeekly Profit Recap & Precise Trade Entry Recommendations - ulpravda.ru
How Assembly Biosciences Inc. stock reacts to global recession fearsPrice Action & Advanced Technical Signal Analysis - ulpravda.ru
Why Assembly Biosciences Inc. (V7B) stock is a must watch ticker2025 Stock Rankings & Consistent Growth Equity Picks - ulpravda.ru
Is Assembly Biosciences Inc. stock attractive after correction2025 AllTime Highs & Short-Term Trading Opportunity Alerts - ulpravda.ru
What risks investors should watch in Assembly Biosciences Inc. stockMarket Risk Analysis & Weekly High Conviction Ideas - ulpravda.ru
Why Assembly Biosciences Inc. stock remains a top recommendation2026 world cup usa national team third place match star players low block defense winner prediction guide - ulpravda.ru
(ASMB) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Assembly Biosciences (NASDAQ:ASMB) Stock Price Up 4% – Time to Buy? - Defense World
Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
ASMB Stock Price, Forecast & Analysis | ASSEMBLY BIOSCIENCES INC (NASDAQ:ASMB) - Chartmill
Assembly Biosciences (NASDAQ:ASMB) Trading 4% HigherHere's What Happened - MarketBeat
After 25 Years, Recurrent Genital Herpes Treatment Gains Corporate Partner - Vax-Before-Travel
Gilead Sciences exercises option to license Assembly Biosciences Helicase-Primase Inhibitor programs for... - Medical Dialogues
Ellsworth Advisors LLC Acquires New Holdings in Assembly Biosciences, Inc. $ASMB - Defense World
Assembly Biosciences stock jumps after Wall Street says Gilead opt-in 'significantly de-risks' genital herpes programs - MSN
Technical Reactions to ASMB Trends in Macro Strategies - Stock Traders Daily
With 32% ownership, Assembly Biosciences, Inc. (NASDAQ:ASMB) has piqued the interest of institutional investors - Yahoo Finance
Assembly Biosciences price target raised to $40 from $29 at Mizuho - MSN
Assembly Biosciences (NASDAQ:ASMB) Stock Price Down 6%What's Next? - MarketBeat
GILD Exercises Option to License Assembly Bio's Herpes Programs - WV News
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes - BioSpace
Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes - Sahm
Assembly Biosciences (NASDAQ:ASMB) Receives Buy Rating from HC Wainwright - Defense World
Gilead opt-in ‘significantly de-risks’ Assembly pipeline, says HC Wainwright - MSN
Gilead exercises option for Assembly Bio’s herpes treatment programs By Investing.com - Investing.com South Africa
Gilead Sciences (GILD) Licenses Assembly Bio's Herpes Drug Progr - GuruFocus
HC Wainwright & Co. Reiterates Assembly Biosciences (ASMB) Buy Recommendation - Nasdaq
Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs - Asianet Newsable
Assembly Biosciences (NASDAQ:ASMB) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Assembly Biosciences rises as Gilead opts to license co's HSV therapies - TradingView — Track All Markets
ASMB: HC Wainwright & Co. Reiterates Buy Rating with $50 PT | AS - GuruFocus
Gilead exercises license for Assembly Biosciences herpes programs - Seeking Alpha
Assembly Biosciences' (ASMB) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Program - PharmiWeb.com
Gilead pays $35M to license pair of HSV assets from Assembly Bio pact - Fierce Biotech
Assembly Biosciences (ASMB) Gains Momentum with Gilead Licensing Deal - GuruFocus
Gilead exercises option for Assembly Bio’s herpes treatment programs - Investing.com
Gilead exercises option for Assembly Bio's herpes treatment programs - StreetInsider
Assembly Biosciences (ASMB) Price Target Increased by 24.84% to 48.70 - Nasdaq
Financial Analysis: Teva Pharmaceutical Industries (NYSE:TEVA) versus Assembly Biosciences (NASDAQ:ASMB) - Defense World
Can Assembly Biosciences Inc. stock beat analyst upgradesTrade Risk Assessment & Fast Entry Momentum Alerts - Улправда
Assembly Biosciences announces interim results from ABI-1179, ABI-5366 trials - MSN
How Assembly Biosciences Inc. stock performs in rising dollar environmentEntry Point & Reliable Price Breakout Alerts - Улправда
How resilient is Assembly Biosciences Inc. stock in market downturnsEarnings Summary Report & Scalable Portfolio Growth Methods - Улправда
Why Assembly Biosciences Inc. stock could see breakout soon2025 Trade Ideas & Risk Managed Trade Strategies - Улправда
Recap Report: How Assembly Biosciences Inc. stock performs in rising dollar environmentQuarterly Trade Report & Community Verified Watchlist Alerts - Улправда
Can Assembly Biosciences Inc. stock resist market sell offsJuly 2025 PreEarnings & Real-Time Volume Analysis Alerts - Улправда
Finanzdaten der Assembly Biosciences Inc-Aktie (ASMB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Assembly Biosciences Inc-Aktie (ASMB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bjorkquist Jeanette M | Principal Accounting Officer |
Mar 31 '25 |
Sale |
9.85 |
180 |
1,773 |
4,617 |
| Okazaki Jason A | CEO and President |
Mar 31 '25 |
Sale |
9.85 |
355 |
3,496 |
14,757 |
| White Nicole S | Chief Manufacturing Officer |
Mar 31 '25 |
Sale |
9.85 |
197 |
1,940 |
11,674 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):